GlobeNewswire by notified

Conagen’s Grant Award Opens New Markets for Monoclonal Antibodies

Share

Funding from the Bill & Melinda Gates Foundation for Conagen’s Conamax platform benefits developing countries and patients globally.

Bedford, Mass., March 29, 2022 (GLOBE NEWSWIRE) -- The Bill & Melinda Gates Foundation has given a grant to Conagen to support further development of its Conamax(TM) platform for the production of accessible low-cost and high-quality monoclonal antibodies, benefitting developing countries and patients globally.

The high cost of monoclonal antibody (mAb) production makes blockbuster drugs expensive, limiting the markets in which these molecules can be applied and limiting access to large patient populations in developing and industrialized countries. The reason for high production costs is, in part, intrinsic to the use of mammalian cell expression systems for antibody manufacturing.

“The Conamax platform was originally conceived to address this global unmet need, so we are thrilled to have the support of the Bill & Melinda Gates Foundation to help develop affordable antibody therapeutics,” said Casey Lippmeier, Ph.D., vice president of innovation at Conagen.

With rapid cell growth, human-compatible glycan structures, and demonstrated world-scale fermentation bioprocesses, the Conamax platform holds several advantages over Chinese Hamster Ovary (CHO) cell lines and other mammalian expression systems, as well as other microbial platforms.

The foundation grant funds the bench-scale development of a proof-of-concept study of a continuous purification process, customized to inputs from Conamax and potentially other microbial host organisms. With large-scale advancements, Conagen envisions that this process will be capable of continuously purifying mAbs from material generated in bioreactors with volumes greater than 250,000 liters.

As a significant advantage, the process will not require expensive binding proteins or other expensive column purification steps. This process will enable economies of scale which are not accessible to CHO or other mammalian-derived cell systems while also providing rapid, high-throughput purification of large amounts of antibody.

“Incumbent antibody manufacturing and purification processes based on Chinese Hamster Ovary (CHO) cell lines have brought tremendous advancements to biopharmaceuticals," said Lippmeier. "However, CHO cell systems are comparatively low volume, expensive, and do not enable low cost and efficient purification of large amounts of antibodies.”

According to McKinsey, in 2019, global sales revenue for all mAb drugs was nearly $163 billion, representing about 70% of the total sales for all biopharmaceutical products, approximately $230 billion. That is about a 50% growth in sales and proportion since 2013, when it was $75 billion.

Continued growth in sales of currently approved mAb products, along with more than 1,200 mAb product candidates currently in development — many for multiple indications — will continue to drive the overall sales of all biopharmaceutical products.

“We’re unlocking the way to make drugs more affordable and, while doing so, opening additional markets for biologics,” said Lippmeier. 

###

About Conagen
Conagen is a product-focused synthetic biology R&D company with large-scale manufacturing service capabilities. Our scientists and engineers use the latest synthetic biology tools to develop high-quality, sustainable, nature-based products by precision fermentation and enzymatic bioconversion. We focus on the bioproduction of high-value ingredients for food, nutrition, flavors and fragrances, pharmaceutical, and renewable materials industries. www.conagen.com

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Game studio Omnigame picks Agillic to scale personalisation and international growth16.5.2022 10:30:00 CEST | Press release

Press release, Copenhagen, 16 May 2022 OmnigameApS is an independent Danish online game studio on an ambitious mission to deliver quality, highly entertaining games and boost player engagement through its new communication strategy. Uncompromising on quality in both their games and customer experience, Omnigame turned to Agillic for operational efficiency, empowering its team to turn its copious data into highly personalised and relevant communication, and to scale the business internationally without ballooning headcounts. With implementation by Agillic Gold Solution Partner NexusOne, Omnigame was up and running on Agillic in less than three months. Since April, it has been leveraging the platform to run automated customer journeys, using content, personalisation and language versions dynamically across three owned channels - with room to scale. Omnigame’s Head of CX, Pia Nørland, says: ‘We are really excited to have started with Agillic. With the first flows already in place and runn

Stockwik förvärvar Cordinator Medical Service16.5.2022 10:00:00 CEST | Pressemelding

Solna den 16 maj 2022 PRESSMEDDELANDE Stockwik Förvaltning AB (publ) har ingått avtal om förvärv av Cordinator Medical Service AB (”Cordinator”). Stockwik förvärvar samtliga aktier i Cordinator. Som ett av Östergötlands ledande företag inom sitt verksamhetsområde företagshälsovård och privat sjukvård kompletterar Cordinator på ett utmärkt sätt Stockwiks övriga företag inom segmentet; TEAM Hälsa, Hela Företagshälsovård, Tjugonde Friskvård och Hälsobolaget. Med Cordinators verksamhet i Linköping och Norrköping täcker vi nu en stor del av Sverige. På Cordinators kliniker finns idag ca 30 anställda och konsulter. Verksamheten har bedrivits av Gunilla Rundqvist sedan 2004 med fokus på kvalitet och kundnöjdhet. För den senaste tolvmånadersperioden, per den 30 april 2022, uppgick Cordinators nettoomsättning till 26 MSEK. EBITDA-resultatet uppgick för motsvarande period till knappa 4 MSEK. Transaktionen sker på skuldfri basis till en EBITDA-multipel 6x. BAKGRUND OCH MOTIV Förvärvet av Cordinat

Grayscale Investments® Launches First European ETF: Grayscale Future of Finance UCITS ETF16.5.2022 09:00:00 CEST | Press release

Grayscale Future of Finance UCITS ETF (ticker: GFOF) listed on select exchanges across Europe Grayscale’s first European ETF accelerates its global strategic expansion NEW YORK, May 16, 2022 (GLOBE NEWSWIRE) -- Grayscale Investments®, the world’s largest digital currency asset manager, today announced its first European ETF, Grayscale Future of Finance UCITS ETF (ticker: GFOF), will list on the London Stock Exchange (LSE), Borsa Italiana, and Deutsche Börse Xetra. GFOF UCITS ETF will also be passported for sale across Europe. GFOF UCITS ETF tracks the investment performance of the Bloomberg Grayscale Future of Finance Index and seeks to offer investors exposure to companies at the intersection of finance, technology, and digital assets – companies that are building the digital economy – all through the familiar ETF wrapper. In February 2022, Grayscale listed an ETF in the United States that tracks the investment performance of the Bloomberg Grayscale Future of Finance Index. The Bloomb

Scandinavian Tobacco Group A/S: Transactions in connection with share buy-back programme16.5.2022 08:45:00 CEST | Press release

Company Announcement No. 33/2022 Copenhagen, 16 May 2022 Transactions in connection with share buy-back programme On 9 March 2022, Scandinavian Tobacco Group A/S (“STG”) announced that a share buy-back programme of an aggregated price of up to DKK 700 million was launched with the purpose to adjust the Company’s capital structure and meet obligations relating to the Group’s share-based incentive programme. The buy-back programme is executed in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (the “Market Abuse Regulation”) and Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules. The share buy-back programme will end no later than 28 February 2023. The following transactions have been executed from 9 May to 12 May 2022: Number of sharesAverage purchase price, DKKTransaction value, DKKAccumulated, last announcement737,564104,827,453 9 May 202222,530147.253,317,65110 May 202220,250151.163,061,06311 May 2